Tacrolimus Market Trends

Tacrolimus Market Trends

The increasing prevalence of autoimmune disorders, coupled with surging research and development activities aimed at developing more effective and promising drugs, is anticipated to emerge as the key contributors propelling the growth trajectory of the market.
 

• The surge in research and development activities in immunosuppression is primarily driven by the increasing incidence of autoimmune diseases. For instance, autoimmune diseases affect up to 8% of the U.S. population, making them among the most prevalent disorders in the country. To address the anticipated population affected due to autoimmune disease diagnostics, there's a growing demand for advanced solutions in immunosuppression.
   
• Additionally, in response to this need, new immunosuppressive agents like the JAK inhibitor tofacitinib and mTOR inhibitor everolimus have been developed, showing promising therapeutic effects in clinical use compared to existing drugs. These new agents are designed to be more selective and have fewer side effects, driving the demand for technological advancements in immunosuppression. This rising prevalence of autoimmune diseases underscores the necessity for such developments, leading to an expanding market in this field.